Información del artículo
Introducción
La MMP-13 (colagenasa-3) es una metaloproteinasa con una potente actividad degradativa contra variados elementos de la matriz extracelular. Se ha descrito su expresión en algunos carcinomas humanos, donde parece desempeñar un papel en la progresión tumoral y metástasis. El objetivo de este estudio fue investigar la expresión y significación clínica de la MMP-13 en carcinomas gástricos.
Pacientes Y MétodoLa expresión de MMP-13 fue analizada por método inmunohistoquímico en los tumores de 44 pacientes tratados quirúrgicamente por adenocarcinoma gástrico, que fueron sometidos a un período medio (± error estándar) de seguimiento clínico de 21,4 ± 3,2 meses.
ResultadosUn total de 14 carcinomas gástricos (31,8%) presentaron una tinción inmunohistoquímica positiva para la MMP-13. El porcentaje de tumores positivos para la enzima fue significativamente (p = 0,009) más elevado en los carcinomas en estadio IV (69,2%) en relación con los carcinomas con estadios inferiores (I, 22,2%; II, 12,5%, y III, 14,3%), así como también en los tumores no resecables (R1 y R2) (61,5%) en relación con los resecables (R0) (19,4%) (p = 0,017). Asimismo, la expresión tumoral de MMP-13 estuvo significativamente asociada con una menor supervivencia total en el conjunto de los pacientes (p = 0,0006) y en el subgrupo de enfermos con carcinomas resecables (p = 0,018).
ConclusionesNuestros resultados sugieren que la expresión tumoral de MMP-13 está asociada con una mayor agresividad tumoral y un peor pronóstico de los pacientes en el cáncer gástrico.
Background
MMP-13 (collagenase-3) is a metalloproteinase with potent degradative activity against a variety of elements of the extracellular matrix. Its expression has been described in some human carcinomas, where it seems to play a role in tumor progression and metastasis.
The objective of this study was to investigate the expression and clinical significance of MMP-13 in gastric carcinomas.
Patients and MethodMMP-13 expression was analyzed by immunohistochemistry in resected specimens from 44 patients with gastric adenocarcinoma. The mean (± standard error) follow-up period was 21.4 ± 3.2 months.
ResultsA total of 14 gastric carcinomas (31.8%) showed positive immunostaining for MMP-13. The percentage of MMP-13-positive tumors was significantly (p = 0.009) higher in stage IV carcinomas (69.2%) than in lower stages (I: 22.2%; II: 12.5%; and III: 14.3%), as well as in nonresectable tumors (R1 and R2) (61.5%) than in resectable carcinomas (R0) (19.4%) (p = 0.017). Likewise, MMP-13 tumor expression was significantly associated with shortened overall survival in both the entire group of patients (p = 0.0006) and in the subgroup of patients with resectable tumors (p = 0.018).
ConclusionsOur results suggest that, in patients harboring gastric adenocarcinoma, MMP-13 tumor expression is associated with higher tumor aggressiveness and a poor prognosis.
El Texto completo está disponible en PDF
Biblografía
[1.]
F.J. Vizoso, A. Martínez, J. Vázquez, M.L. Lamelas, A. Rodil, J.L. García-Muñiz.
Significación biológica y clínica de las enzimas proteolíticas y sus inhibidores en los carcinomas humanos.
Cir Esp, 68 (2000), pp. 471-485
[2.]
Z. Werb, C. Alexander, R. Adler.
Expression and function of matrix metalloproteinases in development.
Marix, (1992), pp. 337-343
[3.]
M. Jeziorska, H. Nagase, L.A. Salamonsen, D.E. Woolley.
Immunolocalization of the matrix metalloproteinases gelatinase B and stromalysin 1 in human endometrium throught the menstrual cycle.
J Reproduction Fertility, 107 (1996), pp. 43-51
[4.]
M. Fini, M. Girard, M. Matsubara.
Collagenolytic/gelatinolytic enzymes in corneal wound healing.
Acta Ophthalmol, 70 (1992), pp. 26-33
[5.]
I. Shima, Y. Sasaguri, J. Kusukawa, H. Yamana, H. Fujita, T. Kakegawa, et al.
Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behabiour of esophageal carcinoma.
Cancer, 70 (1992), pp. 2747-2753
[6.]
L.M. Matrisian.
Metalloproteinases and their inhibitors in matrix remodelling.
Trends Gen, 6 (1990), pp. 121-125
[7.]
M. Egeblad, Z. Werb.
New functions for the matrix metalloproteinases in cancer progression.
Nature Rev Cancer, 2 (2002), pp. 161-174
[8.]
E. Ouchi, K. Imai, Y. Fujii, H. Sato, M. Seiki, Y. Okada.
Membrane type I matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules.
J Biol Chem, 272 (1997), pp. 2446-2451
[9.]
J.M. Freije, I. Díez-Itza, M. Balbín, L.M. Sánchez, R. Blasco, J. Tolivia, et al.
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
J Biol Chem, 269 (1994), pp. 16766-16773
[10.]
P.G. Mitchell, H.A. Magna, L.M. Reeves, L.L. Lopresti-Morrow, S.A. Yocum, P.J. Rosner, et al.
Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.
J Clin Investig, 97 (1996), pp. 761-768
[11.]
O. Lindy, Y.T. Konttinen, T. Sorsa, Y. Ding, S. Santavirta, A. Ceponis, et al.
Matrix metalloproteinase 13 (collagenase-3) in human rheumatoid synovium.
Arthritis Rheum, 40 (1997), pp. 1391-1399
[12.]
V. Knäuper, S. Cowell, B. Smith, C. Lópex-Otín, M. O'Shea, H. Morris, et al.
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3.
J Biol Chem, 40 (1997), pp. 7608-7616
[13.]
J.L. Ashworth, G. Murphy, M.J. Rock, M.J. Sherratt, S.D. Shapiro, C.A. Shuttleworth, et al.
Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling.
Biochem J, 340 (1999), pp. 171-181
[14.]
M. Stahle-Bäckdahl, B. Sandstedt, K. Bruce, A. Lindahl, M.G. Jiménez, J.A. Vega, et al.
Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and rheumathoid arthritis.
Lab Invest, 76 (1997), pp. 717-728
[15.]
M. Balbín, A. Fueyo, J.M. López, I. Díez-Itza, G. Velasco.
López-Otín C. Expression of collagenase-3 in the rat ovary during the ovulatory process.
J Endocrinol, 149 (1996), pp. 405-415
[16.]
L.A. Rudolph-Owen, D.L. Hulboy, C.L. Wilson, J. Mudhett, L.M. Matrisian.
Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice.
Endocrinology, 138 (1997), pp. 4902-4911
[17.]
J.A. Uría, M. Balbín, J.M. López, J. Álvarez, F. Vizoso, M. Takigawa, et al.
Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.
Am J Pathol, 153 (1998), pp. 91-101
[18.]
N. Johansson, K. Airola, R. Grenman, A.L. Kariniemi, U. Saarialho-Kere, V.M. Kahari.
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.
Am J Pathol, 151 (1997), pp. 499-508
[19.]
M. Cazorla, L. Hernández, A. Nadal, M. Balbín, J.M. López, F. Vizoso, et al.
Collagenase-3 expression is asociated with advanced local invasion in human squamous cell carcinomas of the larynx.
J Pathol, 186 (1998), pp. 144-150
[20.]
K. Airola, N. Johansson, A.L. Kariniemi, V.M. Kahari, U.K. Saarialho-Kere.
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
J Investig Dermatol, 109 (1997), pp. 225-231
[21.]
K. Airola, T. Karonen, M. Vaalamo, J. Lohi, A.L. Kariniemi, J. Keski-Oja, et al.
Expression of collagenases-1 and -3 correlates with the level of invasion in malignant melanomas.
Br J Cancer, 80 (1999), pp. 733-743
[22.]
N. Johansson, M. Vaalamo, S. Grenman, S. Hietanen, P. Klemi, U. Saarialho-Kere, et al.
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Am J Pathol, 154 (1999), pp. 469-480
[23.]
P.J. Bostrom, L. Ravanti, N. Reunanen, V. Aaltonen, K.O. Soderstrom, V.M. Kahari, et al.
Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder.
Int J Cancer, 88 (2000), pp. 417-423
[24.]
T. Etoh, H. Inoue, Y. Yoshikawa, G.F. Barnard, S. Kitano, M. Mori.
Increased expression of collagenase-3 (MMP-13) and MTIMMP in oesophageal cancer is related to cancer aggressiveness.
Gut, 47 (2000), pp. 50-56
[25.]
M. Vaalamo, M.L. Karjalainen-Lindsberg, P. Puolakkainen, J. Kere, U. Saarialho-Kere.
Distinct expression profiles of stromalysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinase-3 (TIMP-3) in intestinal ulcerations.
Am J Pathol, 152 (1998), pp. 1005-1014
[26.]
V.J. Uitto, K. Airola, M. Vaalamo, N. Johansson, E.E. Putnins, J.D. Firth, et al.
Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation.
Am J Pathol, 152 (1998), pp. 1489-1499
[27.]
J. Pérez-Ramos, S. de Lourdes, B. Vanda, M. Selman, A. Pardo.
Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis.
Am J Respir Crit Care Med, 160 (1999), pp. 1274-1282
[28.]
G.K. Sukhova, U. Schonbeck, E. Rabkin, F.J. Schoen, A.R. Poole, R.C. Billinghurst, et al.
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.
Circulation, 99 (1999), pp. 2503-2509
[29.]
D. Mao, J.K. Lee, S.J. Van Vickle, R.W. Thompson.
Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smouth muscle cells in culture.
Biochem Biophys Res Commun, 261 (1999), pp. 904-910
[30.]
L.R. Lund, J. Romer, T.H. Bugge, B.S. Nielsen, T.L. Frandsen, J.L. Degen, et al.
Functional overlap between two classes of matrix-degrading proteases in wound healing.
EMBO J, 18 (1999), pp. 4645-4656
[31.]
B.S. Nielsen, F. Rank, J.M. López, M. Balbín, F. Vizoso, L.R. Lund, et al.
Collagenase-3 expression in breast myofibroblasts as a marker of transition of ductal carcinoma in situ lesions to invasive ductal.
Cancer Res, 61 (2001), pp. 7091-7100
[32.]
P. Hermanek, L.H. Sobin.
UICC TNM classification of malignant tumors (4th ed.).
[33.]
P. Lauren.
The two histological main types of gastric carcinoma: diffuse and so called intestinal type carcinomas: an attemp at a histological classification.
Acta Pathol Microbiol Scand, 64 (1965), pp. 31-49
[34.]
J.L. Vaitukaitis.
Production of antisera with small doses of immunogen multiple intradermal injections.
Methods Enzymol, 73 (1981), pp. 46-52
[35.]
E.L. Kaplan, P. Meier.
Nonparametric estimation from incomplete observations.
J Am Stat Assoc, 53 (1958), pp. 457-481
[36.]
N. Mantel, M. Myers.
Problems of convergence of maximum likehood iterative procedures in multiparameter situations.
J Am Statis Assoc, 66 (1971), pp. 484-491
[37.]
D.R. Cox.
Regression models and life tables.
J R Statist Soc B, 34 (1972), pp. 187-220
[38.]
BMDP statistical software. Release 1990,
[39.]
W.F. Grigioni, A. D'Errico, C. Fortunato, M. Florentino, A.M. Mancini, W.G. Stetler-Stevenson, et al.
Prognosis of gastric carcinoma revealed by interactions between tumors cells and basement membrane.
Mod Pathol, 7 (1994), pp. 220-225
[40.]
G.J. Nuovo, P.B. McConell, A. Simsir, F. Valea, D.L. French.
Correlation of the in situ detection of polymerase chain reactionamplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.
Cancer Res, 55 (1995), pp. 267-275
[41.]
C.M.F. Sier, F.J. Kubben, S. Ganesh, M.M. Heerding, G. Griffioen, R. Hanemaaijer, et al.
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Br J Cancer, 74 (1996), pp. 413-417
[42.]
H. Allgayer, R. Babic, B.C.M. Beyer, K.U. Grützner, A. Tarabichi, F.W. Schildberg.
Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Oncol, 55 (1998), pp. 152-160
[43.]
M. Honda, M. Mori, H. Ueo, K. Sugimachi, T. Akiyoshi.
Matrix metalloproteinase-7 expression in gastric carcinoma.
GUT, 39 (1996), pp. 444-448
[44.]
A. Senota, F. Itoh, H. Yamamoto, Y. Adachi, Y. Hinoda, K. Imai.
Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer.
Clin Exp Metastasis, 16 (1998), pp. 313-321
[45.]
H. Nomura, H. Sato, M. Seiki, M. Mai, Y. Okada.
Expression of membrane-type matrix metalloproteinase in human gastric carcinomas.
Cancer Res, 55 (1995), pp. 3263-3266
[46.]
V. Knäuper, H. Will, C. López-Otín, B. Smith, S.J. Atkinson, H. Stanton, et al.
Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme.
J Biol Chem, 271 (1996), pp. 17124-17131
[47.]
S. Cowell, V. Knäuper, M.L. Stewart, M.P. D'Ortho, H. Stanton, R.M. Hembry, et al.
Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase.
Biochem J, 331 (1998), pp. 453-458
[48.]
A.F. Chambers, L.M. Matrisian.
Changing views of the role of matrix metalloproteinases in metastasis.
J Natl Cancer Inst, 89 (1997), pp. 1260-1270
[49.]
J.A. Uría, M. Stahle-Bäckdahl, M. Seiki, A. Fueyo.
López-Otín C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions.
Cancer Res, 57 (1997), pp. 4882-4888
[50.]
D.E. Gómez, D.F. Alonso, H. Yoshiji, U.P. Thorgeirsson.
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
Eur J Cell Biol, 74 (1997), pp. 111-122
[51.]
B. Davies, P.D. Brown, N. East, M.J. Crimmin, F.K. Balkwill.
A synthetic metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.
Cancer Res, 54 (1994), pp. 2087-2091
[52.]
A.H. Drummond, P. Beckett, E.A. Bone, P.D. Brown, M. Davis, W.A. Galloway, et al.
BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models.
Proc Am Assoc Cancer Res, 36 (1995), pp. 100
[53.]
J. Nemunaitis, C. Poole, J. Primrose, A. Rosemurgy, J. Malfetano, P. Brown, et al.
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for long-term studies.
Clin Cancer Res, 4 (1998), pp. 1101-1111
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
